Amgen’s Xgeva Gains FDA Nod For Use In Rare Bone Tumor
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval of denosumab for giant cell tumor of the bone comes more than a year after Amgen’s failed bid to add a more commercially significant indication for prevention of bone metastases in patients with castrate-resistant prostate cancer.
You may also be interested in...
Amgen Plays Diversity Card In Approach To Cancer; Immunotherapy Could Be Its Ace
Amgen explains why it has what it takes in immunotherapy, as part of a broader oncology development plan.
Xgeva Rejection Shows What’s Needed For Non-Metastatic CRPC Approvals
As expected, FDA rejected the new indication for Amgen’s bone drug Xgeva in prevention of bone metastases. But the door is still open for other therapies for castration resistant prostate cancer to target earlier stages of disease.
Xgeva Comes Up Short On Clinical Benefit, Has Too Much Risk, ODAC Tells FDA
The oncologic drugs panel rejects an expanded indication for Amgen’s denosumab, saying a 4.2-month delay in progression of bone metastasis in castrate-resistant prostate cancer patients does not offset the risk of osteonecrosis of the jaw.